nach oben

Virchows Archiv

Erschienen in:

01.01.2016 | Annual Review Issue

Endorsing good quality assurance practices in molecular pathology: risks and recommendations for diagnostic laboratories and external quality assessment providers

verfasst von: Lien Tembuyser, Elisabeth M. C. Dequeker

Erschienen in: Virchows Archiv | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Quality assurance is an indispensable element in a molecular diagnostic laboratory. The ultimate goal is to warrant patient safety. Several risks that can compromise high quality procedures are at stake, from sample collection to the test performed by the laboratory, the reporting of test results to clinicians, and the organization of effective external quality assessment schemes. Quality assurance should therefore be safeguarded at each level and should imply a holistic multidisciplinary approach. This review aims to provide an overview of good quality assurance practices and discusses certain risks and recommendations to promote and improve quality assurance for both diagnostic laboratories and for external quality assessment providers. The number of molecular targets is continuously rising, and new technologies are evolving. As this poses challenges for clinical implementation and increases the demand for external quality assessment, the formation of an international association for improving quality assurance in molecular pathology is called for.

Finn WG (2007) Diagnostic pathology and laboratory medicine in the age of “omics”: a paper from the 2006 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 9:431–436. doi:10.2353/jmoldx.2007.070023 PubMedCentralCrossRefPubMed

Hede K (2008) Breast cancer testing scandal shines spotlight on black box of clinical laboratory testing. J Natl Cancer Inst 100(836–837):844. doi:10.1093/jnci/djn200

Dietel M, Johrens K, Laffert M, Hummel M, Blaker H, Muller BM, Lehmann A, Denkert C, Heppner FL, Koch A, Sers C, Anagnostopoulos I (2013) Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 20:211–221. doi:10.1038/cgt.2013.13 CrossRefPubMed

Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foa R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305–2315. doi:10.1056/NEJMoa1014209 PubMedCentralCrossRefPubMed

Foltran L, Maglio GD, Pella N, Ermacora P, Aprile G, Masiero E, Giovannoni M, Iaiza E, Cardellino GG, Lutrino SE, Mazzer M, Giangreco M, Pisa FE, Pizzolitto S, Fasola G (2015) Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer. Future Oncol 11:629–640. doi:10.2217/fon.14.279 CrossRefPubMed

Seppala TT, Bohm JP, Friman M, Lahtinen L, Vayrynen VM, Liipo TK, Ristimaki AP, Kairaluoma MV, Kellokumpu IH, Kuopio TH, Mecklin JP (2015) Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer 112:1966–1975. doi:10.1038/bjc.2015.160 CrossRefPubMed

Sorbye H, Dragomir A, Sundstrom M, Pfeiffer P, Thunberg U, Bergfors M, Aasebo K, Eide GE, Ponten F, Qvortrup C, Glimelius B (2015) High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLoS One 10:e0131046. doi:10.1371/journal.pone.0131046 PubMedCentralCrossRefPubMed

Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen J, Meyerhardt JA, Fuchs CS, Ogino S (2013) Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105:1151–1156. doi:10.1093/jnci/djt173 PubMedCentralCrossRefPubMed

Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034. doi:10.1056/NEJMoa1305275 CrossRefPubMed

10.

Bokemeyer C, Köhne C-H, Ciardiello F, Lenze H-J, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S (2015) FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 51:1243–1252. doi:10.1016/j.ejca.2015.04.007 CrossRefPubMed

11.

Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjo A, Rouleau E, Sole F, Thunnissen E, Timens W, Schuuring E, Dequeker E, Murray S, Dietel M, Groenen P, Van Krieken JH, European Society of Pathology Task Force on Quality Assurance in Molecular P, Royal College of P (2014) Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol 67:923–931. doi:10.1136/jclinpath-2014-202404 CrossRef

12.

Tack V, Ligtenberg MJ, Tembuyser L, Normanno N, Vander Borght S, Han van Krieken J, Dequeker EM (2015) External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. Oncologist 20:257–262. doi:10.1634/theoncologist.2014-0382 CrossRefPubMed

13.

Tembuyser L, Tack V, Zwaenepoel K, Pauwels P, Miller K, Bubendorf L, Kerr K, Schuuring E, Thunnissen E, Dequeker EM (2014) The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization. PLoS One 9:e112159. doi:10.1371/journal.pone.0112159 PubMedCentralCrossRefPubMed

14.

International Organization for Standardization (2012) ISO 15189:2012 Medical laboratories—particular requirements for quality and competence. ISO, Geneva

15.

Normanno N, Rachiglio AM, Roma C, Fenizia F, Esposito C, Pasquale R, La Porta ML, Iannaccone A, Micheli F, Santangelo M, Bergantino F, Costantini S, De Luca A (2013) Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem 114:514–524. doi:10.1002/jcb.24401 CrossRefPubMed

16.

Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P (2013) Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 93:252–259. doi:10.1038/clpt.2012.237 PubMedCentralCrossRefPubMed

17.

Official Journal of the European Communities (1998) Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices.

18.

European Medicines Agency http://www.ema.europa.eu/ema/. Accessed April 27, 2015.

19.

U.S. Food and Drug Administration http://www.fda.gov/. Accessed April 27, 2015.

20.

Dubbink HJ, Deans ZC, Tops BB, van Kemenade FJ, Koljenovic S, van Krieken HJ, Blokx WA, Dinjens WN, Groenen PJ (2014) Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. Mol Oncol 8:830–839. doi:10.1016/j.molonc.2014.03.004 CrossRefPubMed

21.

Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E (2012) Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30:3570–3577. doi:10.1200/JCO.2012.42.2592 CrossRefPubMed

22.

Chen CC, Er TK, Liu YY, Hwang JK, Barrio MJ, Rodrigo M, Garcia-Toro E, Herreros-Villanueva M (2013) Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations. PLoS One 8:e55793. doi:10.1371/journal.pone.0055793 PubMedCentralCrossRefPubMed

23.

Kircher SM, Mohindra N, Nimeiri H (2015) Cost estimates and economic implications of expanded RAS testing in metastatic colorectal cancer. Oncologist 20:14–18. doi:10.1634/theoncologist.2014-0252 PubMedCentralCrossRefPubMed

24.

Salto-Tellez M, Gonzalez de Castro D (2014) Next-generation sequencing: a change of paradigm in molecular diagnostic validation. J Pathol 234:5–10. doi:10.1002/path.4365 CrossRefPubMed

25.

McCourt CM, McArt DG, Mills K, Catherwood MA, Maxwell P, Waugh DJ, Hamilton P, O’Sullivan JM, Salto-Tellez M (2013) Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One 8:e69604. doi:10.1371/journal.pone.0069604 PubMedCentralCrossRefPubMed

26.

Gullapalli RR, Lyons-Weiler M, Petrosko P, Dhir R, Becich MJ, LaFramboise WA (2012) Clinical integration of next-generation sequencing technology. Clin Lab Med 32:585–599. doi:10.1016/j.cll.2012.07.005 PubMedCentralCrossRefPubMed

27.

Bennett NC, Farah CS (2014) Next-generation sequencing in clinical oncology: next steps towards clinical validation. Cancers 6:2296–2312. doi:10.3390/cancers6042296 PubMedCentralCrossRefPubMed

28.

EuroGentest (2014) Guidelines for diagnostic next generation sequencing. http://www.eurogentest.org/fileadmin/templates/eugt/pdf/NGS_Guidelines/EuroGentest_NGS_guidelines_2014_-_final_draft_02-12-2014_v2.pdf. Accessed 8 April 2015

29.

Meldrum C, Doyle MA, Tothill RW (2011) Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 32:177–195PubMedCentralPubMed

30.

Ulahannan D, Kovac MB, Mulholland PJ, Cazier JB, Tomlinson I (2013) Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br J Cancer 109:827–835. doi:10.1038/bjc.2013.416 PubMedCentralCrossRefPubMed

31.

New York State Department of Health “Next Generation” Sequencing (NGS) guidelines for somatic genetic variant detection. http://www.wadsworth.org/labcert/TestApproval/forms/NextGenSeq_ONCO_Guidelines.pdf. Accessed 8 April 2015

32.

Clinical and Laboratory Standards Institute (2014) Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline—Second Edition. CLSI document MM09-A2 (ISBN 1-56238-953-X)

33.

Aziz N, Zhao Q, Bry L, Driscoll DK, Funke B, Gibson JS, Grody WW, Hegde MR, Hoeltge GA, Leonard DG, Merker JD, Nagarajan R, Palicki LA, Robetorye RS, Schrijver I, Weck KE, Voelkerding KV (2015) College of American pathologists’ laboratory standards for next-generation sequencing clinical tests. Arch Pathol Lab Med 139:481–493. doi:10.5858/arpa.2014-0250-CP CrossRefPubMed

34.

Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, Hambuch T, Lu F, Lyon E, Voelkerding KV, Zehnbauer BA, Agarwala R, Bennett SF, Chen B, Chin EL, Compton JG, Das S, Farkas DH, Ferber MJ, Funke BH, Furtado MR, Ganova-Raeva LM, Geigenmuller U, Gunselman SJ, Hegde MR, Johnson PL, Kasarskis A, Kulkarni S, Lenk T, Liu CS, Manion M, Manolio TA, Mardis ER, Merker JD, Rajeevan MS, Reese MG, Rehm HL, Simen BB, Yeakley JM, Zook JM, Lubin IM (2012) Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol 30:1033–1036. doi:10.1038/nbt.2403 CrossRefPubMed

35.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424. doi:10.1038/gim.2015.30 PubMedCentralCrossRefPubMed

36.

Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F, Carreca AP, Taverna S, Vento R, Peeters M, Russo A, Pauwels P (2014) Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Piophys Acta 1846:539–546. doi:10.1016/j.bbcan.2014.10.001

37.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih M, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz Jr LA (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra224. doi:10.1126/scitranslmed.3007094 CrossRef

38.

Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10:472–484. doi:10.1038/nrclinonc.2013.110 CrossRefPubMed

39.

Fleischhacker M, Schmidt B, Weickmann S, Fersching DM, Leszinski GS, Siegele B, Stotzer OJ, Nagel D, Holdenrieder S (2011) Methods for isolation of cell-free plasma DNA strongly affect DNA yield. Clin Chim Acta 412:2085–2088. doi:10.1016/j.cca.2011.07.011 CrossRefPubMed

40.

Gulley ML, Braziel RM, Halling KC, Hsi ED, Kant JA, Nikiforova MN, Nowak JA, Ogino S, Oliveira A, Polesky HF, Silverman L, Tubbs RR, Van Deerlin VM, Vance GH, Versalovic J (2007) Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med 131:852–863PubMed

41.

Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, Penault-Llorca F, Rossi G (2012) EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 461:245–257. doi:10.1007/s00428-012-1281-4 PubMedCentralCrossRefPubMed

42.

van Krieken JH, Normanno N, Blackhall F, Boone E, Botti G, Carneiro F, Celik I, Ciardiello F, Cree IA, Deans ZC, Edsjo A, Groenen PJ, Kamarainen O, Kreipe HH, Ligtenberg MJ, Marchetti A, Murray S, Opdam FJ, Patterson SD, Patton S, Pinto C, Rouleau E, Schuuring E, Sterck S, Taron M, Tejpar S, Timens W, Thunnissen E, van de Ven PM, Siebers AG, Dequeker E (2013) Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch 462:27–37. doi:10.1007/s00428-012-1354-4 CrossRefPubMed

43.

Garrido P, de Castro J, Concha A, Felip E, Isla D, Lopez-Rios F, Paz-Ares L, Ramirez J, Sanz J, Gomez JJ (2012) Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol 14:338–349. doi:10.1007/s12094-012-0806-2 CrossRefPubMed

44.

Organisation for Economic Co-operation and Development (2007) OECD guidelines for quality assurance in molecular genetic testing. Paris, OECD, 2007

45.

Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, Bafaloukos D, Kosmidis P, Murray S (2011) All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev 37:221–233. doi:10.1016/j.ctrv.2010.07.008 CrossRefPubMed

46.

College of American Pathologists (2014) Laboratory Accreditation Program—Molecular Pathology Checklist

47.

Tembuyser L, Ligtenberg MJ, Normanno N, Delen S, van Krieken JH, Dequeker EM (2014) Higher quality of molecular testing, an unfulfilled priority: results from external quality assessment for KRAS mutation testing in colorectal cancer. J Mol Diagn 16:371–377. doi:10.1016/j.jmoldx.2014.01.003 CrossRefPubMed

48.

Deans ZC, Wallace A, O’Sullivan B, Purvis A, Camus S, Fairley JA, Gonzalez D (2014) External quality assessment of BRAF molecular analysis in melanoma. J Clin Pathol 67:120–124. doi:10.1136/jclinpath-2013-201848 CrossRefPubMed

49.

Breugom AJ, Boelens PG, van den Broek CB, Cervantes A, Van Cutsem E, Schmoll HJ, Valentini V, van de Velde CJ (2014) Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. Ann Oncol 25:1485–1492. doi:10.1093/annonc/mdu039 CrossRefPubMed

50.

Hall JA, Salgado R, Lively T, Sweep F, Schuh A (2014) A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. Lancet Oncol 15:e184–e193. doi:10.1016/S1470-2045(13)70607-7 CrossRefPubMed

51.

International Organization for Standardization (2004) ISO/IEC 17000:2004 - Conformity assessment—vocabulary and general principles. Geneva, ISO, 2004

52.

EU Legislation (2008) Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 setting out the requirements for accreditation and market surveillance relating to the marketing of products and repealing Regulation (EEC) No 339/93, http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1428479329930&uri=URISERV:l33248. Accessed 8 April 2015

53.

Zekerheid FOS (2007) Koninklijk Besluit tot wijziging van de bijlage bij het Koninklijk Besluit van 14 September 1984 tot vaststelling van de nomenclatuur van de geneeskundige verstrekkingen inzake verplichte verzekering voor geneeskundige verzorging en uitkeringen. Belgisch Staatsblad

54.

Deans ZC, Bilbe N, O’Sullivan B, Lazarou LP, de Castro DG, Parry S, Dodson A, Taniere P, Clark C, Butler R (2013) Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment. J Clin Pathol 66:319–325. doi:10.1136/jclinpath-2012-201227 CrossRefPubMed

55.

Normanno N, Pinto C, Taddei G, Gambacorta M, Castiglione F, Barberis M, Clemente C, Marchetti A (2013) Results of the first Italian external quality assurance scheme for somatic EGFR mutation testing in non-small-cell lung cancer. J Thorac Oncol 8:773–778. doi:10.1097/JTO.0b013e31828c2b08 CrossRefPubMed

56.

Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Popat S, Stahel R, Thunnissen E (2014) Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. Br J Cancer 111:413–420. doi:10.1038/bjc.2014.353 PubMedCentralCrossRefPubMed

57.

Marchetti A, Barberis M, Papotti M, Rossi G, Franco R, Malatesta S, Buttitta F, Ardizzoni A, Crino L, Gridelli C, Taddei GL, Clemente C, Scagliotti G, Normanno N, Pinto C (2014) ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first Italian external quality assurance scheme. J Thorac Oncol 9:1470–1476. doi:10.1097/JTO.0000000000000280 CrossRefPubMed

58.

von Laffert M, Penzel R, Schirmacher P, Warth A, Lenze D, Hummel M, Dietel M (2014) Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test. J Thorac Oncol 9:1464–1469. doi:10.1097/JTO.0000000000000307 CrossRef

59.

Berwouts S, Girodon E, Schwarz M, Stuhrmann M, Morris MA, Dequeker E (2012) Improvement of interpretation in cystic fibrosis clinical laboratory reports: longitudinal analysis of external quality assessment data. Eur J Hum Genet 20:1209–1215. doi:10.1038/ejhg.2012.131 PubMedCentralCrossRefPubMed

60.

Dequeker E, Cassiman JJ (1998) Evaluation of CFTR gene mutation testing methods in 136 diagnostic laboratories: report of a large European external quality assessment. Eur J Hum Genet 6:165–175CrossRefPubMed

61.

Ibarreta D, Elles R, Cassiman JJ, Rodriguez-Cerezo E, Dequeker E (2004) Towards quality assurance and harmonization of genetic testing services in the European Union. Nat Biotechnol 22:1230–1235CrossRefPubMed

62.

Dequeker E, Ramsden S, Grody WW, Stenzel TT, Barton DE (2001) Quality control in molecular genetic testing. Nat Rev Genet 2:717–723CrossRefPubMed

63.

van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Flejou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453:417–431. doi:10.1007/s00428-008-0665-y CrossRefPubMed

64.

International Organization for Standardization (2010) ISO/IEC 17043:2010 Conformity assessment—general requirements for proficiency testing. Geneva, ISO, 2010

65.

O’Brien CP, Taylor SE, O’Leary JJ, Finn SP (2014) Molecular testing in oncology: problems, pitfalls and progress. Lung Cancer 83:309–315. doi:10.1016/j.lungcan.2013.12.010 CrossRefPubMed

66.

Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F, on the behalf of the C-Gi (2015) Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol 26(8):1710–1714. doi:10.1093/annonc/mdv176 CrossRef

67.

Thunnissen E, van der Oord K, den Bakker M (2014) Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch 464:347–358. doi:10.1007/s00428-014-1535-4 CrossRefPubMed

68.

Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971. doi:10.1056/NEJMoa1406766 PubMedCentralCrossRefPubMed

Titel: Endorsing good quality assurance practices in molecular pathology: risks and recommendations for diagnostic laboratories and external quality assessment providers
verfasst von: Lien Tembuyser
Elisabeth M. C. Dequeker
Publikationsdatum: 01.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 1/2016
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-015-1839-z

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Endorsing good quality assurance practices in molecular pathology: risks and recommendations for diagnostic laboratories and external quality assessment providers

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Does everything a surgeon takes out have to be seen by a pathologist? A review of the current pathology practice

Ensuring quality in postgraduate medical education: competency testing is the key

Thanks to you

Sense and nonsense in the process of accreditation of a pathology laboratory

Quality assurance in postgraduate pathology training the Dutch way: regular assessment, monitoring of training programs but no end of training examination

Quality in pathology: how good is good? An introduction

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien